Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

  • Quoted phrase not found.
1.

The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.

Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, Halliday D, Pretorius PM, Parry A; , on behalf of the UK NF2 Research Group..

J Neurosurg Spine. 2017 Apr;26(4):474-482. doi: 10.3171/2016.8.SPINE16589. Epub 2016 Dec 16.

PMID:
27982762
2.

High-resolution interrogation of functional elements in the noncoding genome.

Sanjana NE, Wright J, Zheng K, Shalem O, Fontanillas P, Joung J, Cheng C, Regev A, Zhang F.

Science. 2016 Sep 30;353(6307):1545-1549.

3.

Gastric plexiform schwannoma in association with neurofibromatosis type 2.

Kudose S, Kyriakos M, Awad MM.

Clin J Gastroenterol. 2016 Dec;9(6):352-357. Epub 2016 Sep 30. Review.

PMID:
27696205
4.

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration.; REiNS International Collaboration Members 2016..

Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.

PMID:
27527647
5.
6.

Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

Ouerdani A, Goutagny S, Kalamarides M, Trocóniz IF, Ribba B.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1263-73. doi: 10.1007/s00280-016-3046-2. Epub 2016 May 4.

PMID:
27146400
7.

Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14676-81. doi: 10.1073/pnas.1512570112. Epub 2015 Nov 9.

8.

Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.

Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF.

Acta Neurol Scand. 2016 Jun;133(6):475-80. doi: 10.1111/ane.12490. Epub 2015 Sep 15.

PMID:
26369495
9.

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Int J Neurosci. 2016 Nov;126(11):1002-6. doi: 10.3109/00207454.2015.1092443. Epub 2015 Oct 6.

PMID:
26365467
10.

Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.

Li KL, Djoukhadar I, Zhu X, Zhao S, Lloyd S, McCabe M, McBain C, Evans DG, Jackson A.

Neuro Oncol. 2016 Feb;18(2):275-82. doi: 10.1093/neuonc/nov168. Epub 2015 Aug 26.

11.

Cilioretinal Artery Territory Infarction Associated With Papilledema in a Patient With Neurofibromatosis Type 2.

Mahroo OA, Mohamed MD, Graham EM, Mann SS, Plant GT, Afridi SK, Hammond CJ.

J Neuroophthalmol. 2016 Mar;36(1):58-60. doi: 10.1097/WNO.0000000000000279.

PMID:
26295608
12.

The Prevalence of Cochlear Obliteration After Labyrinthectomy Using Magnetic Resonance Imaging and the Implications for Cochlear Implantation.

Charlett SD, Biggs N.

Otol Neurotol. 2015 Sep;36(8):1328-30. doi: 10.1097/MAO.0000000000000803.

PMID:
26134936
13.

Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.

Sponghini AP, Platini F, Rondonotti D, Soffietti R.

Tumori. 2015 Nov 14;101(6):e167-70. doi: 10.5301/tj.5000313.

PMID:
26108240
14.

Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Hochart A, Gaillard V, Baroncini M, André N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Nève V, Sudour Bonnange H, Bonne NX, Leblond P.

J Neurooncol. 2015 Sep;124(2):229-36. doi: 10.1007/s11060-015-1828-8. Epub 2015 May 29.

PMID:
26022982
15.

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M.

J Neurooncol. 2015 Apr;122(2):313-20. doi: 10.1007/s11060-014-1710-0. Epub 2015 Jan 8.

PMID:
25567352
16.

Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2.

Liu A, Kuhn EN, Lucas JT Jr, Laxton AW, Tatter SB, Chan MD.

J Neurosurg. 2015 Mar;122(3):536-42. doi: 10.3171/2014.10.JNS132593. Epub 2015 Jan 2.

PMID:
25555193
17.

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group..

Discov Med. 2014 Dec;18(101):323-30. Review.

18.

Non surgical treatment of vestibular schwannoma.

Arribas L, Chust ML, Menéndez A, Arana E, Vendrell JB, Crispín V, Pesudo C, Mengual JL, Mut A, Arribas M, Guinot JL.

Acta Otorrinolaringol Esp. 2015 Jul-Aug;66(4):185-91. doi: 10.1016/j.otorri.2014.08.003. Epub 2014 Dec 9. English, Spanish.

19.

Neurofibromatosis-related tumors: emerging biology and therapies.

Karajannis MA, Ferner RE.

Curr Opin Pediatr. 2015 Feb;27(1):26-33. doi: 10.1097/MOP.0000000000000169. Review.

20.

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3627-33. doi: 10.1007/s00405-014-3398-3. Epub 2014 Nov 25.

PMID:
25421643

Supplemental Content

Loading ...
Support Center